SRRK Scholar Rock Holding Corp
Company Analysis
Latest News
🟢 Scholar Rock is trading 11.89% up in pre-market after FDA approval of ISEMBYLD
Scholar Rock is trading 11.89% up in pre-market at $62.00 after the FDA approved ISEMBYLD on September 11, 2026, the company’s first approved treatment. - It...
🟢 Scholar Rock is trading 8.21% up in pre-market after FDA approves ISEMBYLD
Scholar Rock is trading 8.21% up at $59.96 after the FDA approved ISEMBYLD on September 11, 2026, the company’s first approved treatment for spinal muscular...
Scholar Rock Lands Its First FDA Approval — But Can a $7 Billion Company With Zero Revenue Justify the Price Tag?
Shares of Scholar Rock surged +13.5% to $62.91 after the FDA cleared Isembyld, its muscle-strengthening treatment for spinal muscular atrophy, vaulting the...
🟢 Scholar Rock is trading 13.5% up in after-hours trading after first FDA approval for SMA therapy
Scholar Rock is trading at $62.91 (+13.54%) after the FDA approved its spinal muscular atrophy therapy on September 11, 2026, marking its first regulatory...
🔴 Scholar Rock is trading 4.3% down today after manufacturing compliance remained FDA’s key issue
Scholar Rock is trading 4.3% down at $54.98 after September 9, 2026 conference commentary highlighted manufacturing compliance as the FDA’s only remaining...
🟢 Scholar Rock is trading 4.5% up today — immediate catalyst remains unclear
Scholar Rock is trading at $57.79, up 4.45% on September 8, 2026, despite weaker U.S. equities; no verified company-specific announcement has been reported,...
Casdin Capital nearly doubles its stake in clinical-stage biotech Scholar Rock
Life sciences investor Casdin Capital significantly increased its position in Scholar Rock (SRRK), boosting its holdings by 90% to 665,000 shares. According to...
🟢 Scholar Rock is trading 4.43% up today as XBI gains 2.06%
Scholar Rock is trading 4.43% up now at $60.83 amid broad strength across biotechnology stocks, with XBI up 2.06% during regular trading. - No new...